If you followed our trades from November /December you made at least 20% so why push it? The Rayno Life Science Portfolio is down 0.75% today in a choppy  market. Our mid-cap biopharmaceutical index is down 0.87% but diagnostics and tools are  down only 0.3% as they were hit hard over the past 3 months. The IBB hit a high of $114 but is still up 7.7% 2012 YTD, comparable to the QQQ up 6.8% . The bull market in biotech is still intact but the big move over the past two months calls for some profit taking. Our focus trades from Nov./Dec:  Albany Molecular (AMRI $3.12) up 25%,  Astex (ASTX 2.15) up 29%, Dendreon (DNDN $13.10) up 73%, Illumina (ILMN $36.49) up 25%,  SeraCare (SRLS $3.03) up  2.6%.

Notable in today’s action Exelixis (EXEL $4.84) is down 3.2%, Medivation (MDVN $50.31) is down 1.62%, Sequenom(SQNM $4.265) down 2.18%, and Viropharma( VPHM $29) down 2.74%. The speculative HCV trade has also cooled off with Idenix (IDIX $13.8) down 2%.

In the green today on volume are Incyte (INCY $17.98) up 4% and Jazz (JAZZ $47.18) up 2.6%.

Amgen (AMGN), Bristol Myers (BMY) and Johnson and Johnson(JNJ) report earnings this week.

Biotech CEO Stanley Crooke of ISIS ($7.87) offers contrary opinion on Amgen and Regeneron’s cholesterol drugs.

Pin It on Pinterest